» Articles » PMID: 35608504

Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines

Abstract

Background: Comparison of humoral responses in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinees, those with SARS-CoV-2 infection, or combinations of vaccine/ infection ("hybrid immunity") may clarify predictors of vaccine immunogenicity.

Methods: We studied 2660 US Military Health System beneficiaries with a history of SARS-CoV-2 infection-alone (n = 705), vaccination-alone (n = 932), vaccine-after-infection (n = 869), and vaccine-breakthrough-infection (n = 154). Peak anti-spike-immunoglobulin G (IgG) responses through 183 days were compared, with adjustment for vaccine product, demography, and comorbidities. We excluded those with evidence of clinical or subclinical SARS-CoV-2 reinfection from all groups.

Results: Multivariable regression results indicated that vaccine-after-infection anti-spike-IgG responses were higher than infection-alone (P < .01), regardless of prior infection severity. An increased time between infection and vaccination was associated with greater post-vaccination IgG response (P < .01). Vaccination-alone elicited a greater IgG response but more rapid waning of IgG (P < .01) compared with infection-alone (P < .01). BNT162b2 and mRNA-1273 vaccine-receipt was associated with greater IgG responses compared with JNJ-78436735 vaccine-receipt (P < .01), regardless of infection history. Those with vaccine-after-infection or vaccine-breakthrough-infection had a more durable anti-spike-IgG response compared to infection-alone (P < .01).

Conclusions: Vaccine-receipt elicited higher anti-spike-IgG responses than infection-alone, although IgG levels waned faster in those vaccinated (compared to infection-alone). Vaccine-after-infection elicits a greater humoral response compared with vaccine or infection alone; and the timing, but not disease severity, of prior infection predicted these post-vaccination IgG responses. While differences between groups were small in magnitude, these results offer insights into vaccine immunogenicity variations that may help inform vaccination timing strategies.

Citing Articles

Serological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand.

Ward D, Pattarapreeyakul L, Pitaksalee R, Thawong N, Sawaengdee W, Tuntigumthon S Sci Rep. 2025; 15(1):1519.

PMID: 39789037 PMC: 11718049. DOI: 10.1038/s41598-024-84392-2.


Current Status and Significance of Additional Vaccination with COVID-19 Vaccine in Japan-Considerations from Antibody Levels from Hybrid Immunity and Public Perceptions.

Kusunoki H Vaccines (Basel). 2025; 12(12.

PMID: 39772074 PMC: 11680318. DOI: 10.3390/vaccines12121413.


Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China.

Wang K, Zeng T, Guo Z, Liang J, Sun S, Ni Y BMC Infect Dis. 2024; 24(1):1401.

PMID: 39695978 PMC: 11654266. DOI: 10.1186/s12879-024-10250-1.


Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection.

Wiegand R, Fireman B, Najdowski M, Tenforde M, Link-Gelles R, Ferdinands J Nat Commun. 2024; 15(1):10062.

PMID: 39567531 PMC: 11579392. DOI: 10.1038/s41467-024-54404-w.


Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.

Muehleman D, Gruner B, Hogan V, Fanning P, Garrett C, Meyer J Emerg Infect Dis. 2024; 30(14):53-61.

PMID: 39530855 PMC: 11559565. DOI: 10.3201/eid3014.240231.